PMDA drug package insert
テガルナスティックＳＡＲＳ−ＣｏＶ−２ Ａｇ （一般用）
PMDA OTC drug · 藤永製薬株式会社 · package insert Feb 4, 2025
Key facts
| Brand names | テガルナスティックＳＡＲＳ−ＣｏＶ−２ Ａｇ （一般用） |
|---|---|
| Companies | 製造販売元／藤永製薬株式会社 |
| Product type | OTC drug |
| OTC risk class | 第１類医薬品 |
| OTC dosage form | その他 |
| OTC effect category | その他の一般用検査薬 |
| Package insert date | Feb 4, 2025 |
| PMDA document key | 670126_K2501000008 |
| PMDA company code | 670126 |
At a glance
- 1–9 Package insert revisions
- None Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: